



OFFICE of INTELLIGENCE and ANALYSIS

INTELLIGENCE IN FOCUS

23 NOVEMBER 2020

IA-47837-21

ECONOMIC SECURITY

(U//FOUO) Low Threat to COVID-19 Vaccine Shipments in Near Term

(U//FOUO) We assess that the most likely threat to COVID-19 vaccine shipments over the next six months comes from US trade partners, some of which might nationalize components of the COVID-19 vaccine production process abroad or attempt to intercept shipments in their countries bound for the United States. We have low confidence in this judgment because it is based on limited information about foreign actors' intentions and capabilities. We lack reporting that criminal or terrorist actors are planning to target COVID-19 vaccine shipments.

- *(U//FOUO) Last month, a US pharmaceutical company identified social media posts by a nationalist party in Italy advocating the nationalization of vaccines manufactured in Italy, potentially to include intercepting shipments bound for the United States, according to DHS reporting. Italy is one of four European countries participating in the Inclusive Vaccines Alliance, which has lobbied for COVID-19 vaccines to be manufactured in Europe, according to open-source information.*
- *(U//FOUO) In the spring, as the first wave of the COVID-19 pandemic began spreading across the globe, India restricted exports of at least 26 active pharmaceutical ingredients, according to industry and news sources, demonstrating its willingness to use trade measures to prioritize national requirements.*

(U//FOUO) Within the United States, we assess that criminal, terrorist, and state-backed actors would be unable to significantly disrupt COVID-19 vaccine shipments. We base this judgment on security precautions taken by logistics and pharmaceutical companies, including their extensive partnership with public-sector organizations.

- *(U) One of the world's leading cargo companies, which expects to transport 16 billion doses of the COVID-19 vaccine globally, is increasing security around its US and international facilities by restricting access to pharmaceutical zones and adding security fencing, 24/7 CCTV coverage, and intrusion alarm systems, according to Western press reporting. Pharmaceutical companies and hospitals are also incorporating heightened counter-theft measures like GPS tracking and other verification measures to prevent theft of COVID-19 vaccines, according to the same source.*
- *(U) An industry association for manufacturing, transportation, and security stakeholders has developed an incident database that will allow members to identify details and trends about thefts of pharmaceuticals shipments, which will enable transportation companies to avoid high-risk areas and delivery routes, according to an industry news source.*

- (U) Multiple US Government organizations, including the US Army and Centers for Disease Control and Prevention, will support efforts to track shipments of COVID-19 vaccines within the United States, according to their public statements. As part of Operation Warp Speed, the US Government's initiative to jumpstart COVID-19 production, the FBI, CISA, and USMS will also be involved in protecting the physical and cyber security of organizations involved in COVID-19 vaccine distribution, according to industry and US Government information.

(U//FOUO) **Indicators of Terrorist or Criminal Intent to Disrupt COVID-19 Vaccine Shipments**

(U//FOUO) Several indicators would suggest a criminal or terrorist posture may be trying to disrupt COVID-19 vaccine shipments:

- (U) Physical surveillance of pharmaceutical facilities or transportation hubs like airports through conventional methods or UAVs;
- (U) Attempts to gain cyber access to logistics centers and vaccine transportation routes;
- (U) Recruitment of individuals with access to transportation facilities;
- (U) Increase in the percentage of applicants for transportation facility jobs who have derogatory backgrounds; and
- (U) Terrorist publications or social media posts that advocate attacks on COVID-19 vaccine shipments.

Source, Reference, and Dissemination Information

Source Summary Statement	<i>(U//FOUO)</i> We have low confidence in our judgment about the threat to COVID-19 vaccine shipments in the near term. We would have higher confidence with additional or classified information about threats to COVID-19 vaccine supply chains. We base our assessment on US Government reporting and open-source information from credible Western news sources and pharmaceutical and transportation industry publications.
Reporting Suspicious Activity	<i>(U)</i> To report suspicious activity, law enforcement, Fire-EMS, private security personnel, and emergency managers should follow established protocols; all other personnel should call 911 or contact local law enforcement. Suspicious activity reports (SARs) will be forwarded to the appropriate fusion center and FBI Joint Terrorism Task Force for further action. For more information on the Nationwide SAR Initiative, visit http://nsi.ncirc.gov/resources.aspx .
Dissemination	<i>(U)</i> Federal, state, local, tribal, and territorial authorities and private sector security partners.
Warning Notices & Handling Caveats	<p><i>(U)</i> Warning: This document contains UNCLASSIFIED//FOR OFFICIAL USE ONLY (U//FOUO) information that may be exempt from public release under the Freedom of Information Act (5 USC. 552). It is to be controlled, stored, handled, transmitted, distributed, and disposed of in accordance with DHS policy relating to FOUO information and is not to be released to the public, the media, or other personnel who do not have a valid need to know without prior approval of an authorized DHS official. State and local homeland security officials may share this document with critical infrastructure and key resource personnel or private sector security officials without further approval from DHS.</p> <p><i>(U)</i> All US person information has been minimized. Should you require US person information on weekends or after normal weekday hours during exigent and time sensitive circumstances, contact the Current and Emerging Threat Watch Office at 202-447-3688, CETC.OSCO@HQ.DHS.GOV. For all other inquiries, please contact the Homeland Security Single Point of Service, Request for Information Office at DHS-SPS-RFI@hq.dhs.gov, DHS-SPS-RFI@dhs.sgov.gov, DHS-SPS-RFI@dhs.ic.gov.</p>



Product Title:

All survey responses are completely anonymous. No personally identifiable information is captured unless you voluntarily offer personal or contact information in any of the comment fields. Additionally, your responses are combined with those of many others and summarized in a report to further protect your anonymity.

1. Please select partner type: and function:

2. What is the highest level of intelligence information that you receive?

3. Please complete the following sentence: "I focus most of my time on:"

4. Please rate your satisfaction with each of the following:

	Very Satisfied	Somewhat Satisfied	Neither Satisfied nor Dissatisfied	Somewhat Dissatisfied	Very Dissatisfied	N/A
Product's overall usefulness	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Product's relevance to your mission	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Product's timeliness	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Product's responsiveness to your intelligence needs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

5. How do you plan to use this product in support of your mission? (Check all that apply.)

- | | |
|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <input type="checkbox"/> Drive planning and preparedness efforts, training, and/or emergency response operations | <input type="checkbox"/> Initiate a law enforcement investigation |
| <input type="checkbox"/> Observe, identify, and/or disrupt threats | <input type="checkbox"/> Initiate your own regional-specific analysis |
| <input type="checkbox"/> Share with partners | <input type="checkbox"/> Initiate your own topic-specific analysis |
| <input type="checkbox"/> Allocate resources (e.g. equipment and personnel) | <input type="checkbox"/> Develop long-term homeland security strategies |
| <input type="checkbox"/> Reprioritize organizational focus | <input type="checkbox"/> Do not plan to use |
| <input type="checkbox"/> Author or adjust policies and guidelines | <input type="checkbox"/> Other: <input type="text"/> |

6. To further understand your response to question #5, please provide specific details about situations in which you might use this product.

7. What did this product not address that you anticipated it would?

8. To what extent do you agree with the following two statements?

	Strongly Agree	Agree	Neither Agree nor Disagree	Disagree	Strongly Disagree	N/A
This product will enable me to make better decisions regarding this topic.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
This product provided me with intelligence information I did not find elsewhere.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

9. How did you obtain this product?

10. Would you be willing to participate in a follow-up conversation about your feedback?

To help us understand more about your organization so we can better tailor future products, please provide:

Name: <input type="text"/>	Position: <input type="text"/>
Organization: <input type="text"/>	State: <input type="text"/>
Contact Number: <input type="text"/>	Email: <input type="text"/>



[Privacy Act Statement](#)